StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH)

Stock analysts at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the stock.

Separately, Roth Mkm raised their price target on shares of Bio-Path from $12.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, March 27th.

Bio-Path Stock Up 5.9 %

BPTH opened at $3.23 on Tuesday. The firm has a market cap of $2.20 million, a price-to-earnings ratio of -0.08 and a beta of 0.35. Bio-Path has a fifty-two week low of $2.70 and a fifty-two week high of $44.80. The company’s 50-day moving average price is $5.59 and its 200 day moving average price is $8.56.

Bio-Path (NASDAQ:BPTH) last released its quarterly earnings data on Friday, March 8th. The company reported ($5.40) earnings per share for the quarter, hitting the consensus estimate of ($5.40). During the same quarter last year, the business posted ($10.60) EPS. Research analysts anticipate that Bio-Path will post -18.71 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new stake in Bio-Path during the first quarter worth approximately $38,000. Citadel Advisors LLC bought a new stake in Bio-Path during the third quarter worth approximately $35,000. Renaissance Technologies LLC bought a new stake in Bio-Path during the second quarter worth approximately $70,000. Walleye Capital LLC bought a new stake in Bio-Path during the third quarter worth approximately $77,000. Finally, Vanguard Group Inc. boosted its holdings in Bio-Path by 77.5% during the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock worth $125,000 after buying an additional 117,914 shares in the last quarter. 5.74% of the stock is currently owned by institutional investors.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.